Johnson & Johnson (JNJ) — BATS 16/100 — 2026-07-15

Listen to the earnings call audio for free on StockAnalysis

Summary based on Johnson & Johnson earnings call on 2026-07-15

BotFlo AI Transformation Score for $JNJ: 16 (16/100)

Sector AI Transformation Score for $JNJ: 4 (4/50)

Presentation

(1/6) Call opening and agenda
• 📌 Ryan Koors opened J&J’s Q2 2026 review and noted materials are available at investor.jnj.com.
• ⚠️ Management cautioned that the presentation contains forward-looking statements subject to risks in SEC filings including the 2025 Form 10-K.
• 🗣️ Agenda featured CEO Joaquin Duato, IR sales/P&L review, CFO Joe Wolk guidance, and IM/MedTech leaders for Q&A.

(2/6) CEO: accelerated growth and $100B trajectory
• 📈 Duato said 2026 is a year of accelerated growth, with a Q2 beat on top and bottom line and raised guidance.
• 💰 Operational sales grew 5.6%, double digits excluding STELARA, with more than $25 billion in quarterly sales on track for more than $100 billion annual revenue.
• 🚀 New launches including ICOTYDE, INLEXZO and RYBREVANT support confidence in acceleration into 2027 and double-digit growth by decade end.

(3/6) Innovative Medicine: oncology, immunology, neuroscience
• 💊 Innovative Medicine operational sales grew 6.8%, with oncology led by DARZALEX above $4 billion and high-teens growth plus strong CARVYKTI, TECVAYLI and TALVEY.
• 🧬 J&J aims to be the #1 oncology company by 2030 with sales projected to exceed $50 billion and is adding FireFly Bio after Halda.
• 📊 TREMFYA grew 71%, ICOTYDE topped 10,000 initiated patients, and CAPLYTA new patient starts rose 122% versus prior year.

(4/6) MedTech: cardiovascular, surgery robotics, vision
• ❤️ MedTech operational sales grew 3.6%, with VARIPULSE treating more than 85,000 Afib patients and debut of CARTO Sound Sonata AI-powered imaging and mapping.
• 🤖 Surgery is advancing OTTAVA, described as a potentially first stable integrated robotic system with automated features and a digital ecosystem for data-driven insights.
• 👁️ Vision accelerated TECNIS PureSee availability and announced more than $1 billion to scale U.S. vision manufacturing as part of a $55 billion U.S. commitment.

(5/6) Q2 financial results detail
• 💵 Worldwide sales were $25.3 billion, up 5.6% operationally despite about 460 basis points of STELARA headwind.
• 📉 Adjusted diluted EPS was $2.90, up 4.7%, while Innovative Medicine and MedTech margins dipped slightly on launch investment, mix, R&D and tariffs.
• 🏥 MedTech growth of 3.6% reflected Shockwave strength but EP China inventory and Abiomed procedure selectivity headwinds.

(6/6) CFO capital allocation and raised 2026 guidance
• 🏦 J&J ended Q2 with about $21 billion cash and marketable securities, about $49 billion debt, and year-to-date free cash flow of about $8.7 billion.
• 📈 Operational sales guidance was raised by $400 million to 6.5%–7.1% growth with midpoint $100.6 billion, and adjusted operational EPS to $11.50–$11.65.
• 🧭 Pretax operating margin improvement expectation rose to about 75 basis points, with multiple H2 pipeline and MedTech catalysts and Orthopedics separation on track for mid-2027.

Q&A

(1/9) Q&A: What drives the $400 million operational sales guidance raise across pharma versus MedTech?
• 💊 Wolk said it is fair to characterize pharma moving higher, with second-half strength from early launches such as ICOTYDE, INLEXZO and TREMFYA IBD.
• 🏥 He still expects MedTech to grow better in the second half than the first half.
• ❤️ Abiomed expectations were tempered to more modest growth until PROTECT 4, with recovery more into next year.

(2/9) Q&A: How is the ICOTYDE launch tracking on patients, prescribers, access, and TREMFYA co-positioning?
• 🚀 Taubert reported over 18,000 prescriptions, about 11,000 patients, 6,000 unique prescribers, and more than 50% commercial coverage within 90 days.
• 🧩 ICOTYDE is positioned as first-choice systemic therapy while TREMFYA remains first-choice biologic, with both growing and TREMFYA psoriasis/PsA share gains continuing.
• 📣 J&J is investing to win, including starting ICOTYDE DTC advertising, while Reed noted upcoming PsA pivotal data and ongoing IBD Phase III studies.

(3/9) Q&A: What are U.S. procedure trends and second-half MedTech growth expectations?
• 📊 Schmid said procedure volumes remain stable with no evidence of a broad-based demand slowdown, and Surgery, Vision, and Orthopedics all accelerated.
• ⚠️ CV was muted by a roughly 400 basis-point China EP inventory hit and slower Impella use after a neutral U.K. trial, partly offset by double-digit Shockwave growth.
• 📈 Management expects H2 acceleration from Vision, Orthopedics, Surgery and CV improvement, and does not see material ACA-subsidy impact on MedTech demand.

(4/9) Q&A: How are TECVAYLI label expansion and community uptake affecting growth?
• 💰 TECVAYLI quarterly sales were $260 million, driven by launch uptake and share gains in earlier lines after U.S. approval with DARZALEX.
• 📉 She highlighted extraordinary combination data, with 83% of patients alive and progression-free at 3 years.
• 🏥 U.S. sequential patient initiations rose 29%, most starts are now second-to-third line, and community sites expanded 25% quarter-over-quarter.

(5/9) Q&A: What is the update on the robotics portfolio and near-term launches?
• 🤖 Schmid said J&J is awaiting OTTAVA approval after a late-last-year submission and is running a second clinical trial focused on inguinal hernia.
• 🚀 Assuming approvals, J&J remains committed to two large robotic launches this year: differentiated OTTAVA and Monarch for urology.
• 📈 Duato added that OTTAVA and Monarch are expected to be meaningful MedTech growth contributors by the end of the decade.

(6/9) Q&A: How is INLEXZO launching and what should investors expect from Sunrise data?
• 📈 Taubert said INLEXZO is outperforming recent competitive launches, with one in three eligible patients starting therapy and new patient insertions up 75% after the permanent J-code.
• 💵 Although sales are not yet broken out, J&J said it beat consensus and more than doubled second-quarter sales versus the first quarter.
• 🧬 Reed framed Sunrise expansion from CIS into papillary and BCG-naive populations, citing highest complete response rates seen in the approved setting and follow-on erdafitinib device potential.

(7/9) Q&A: What is the confidence and timing outlook for milvexian in AFib?
• ⏱️ Reed said milvexian studies are fully recruited and event-driven, so readout could be late this year or early next year without a fixed date.
• ✅ He remains confident in AFib dosing based on Phase II and biomarkers, with the DMC telling the program to go full steam ahead.
• 💡 Taubert and Reed emphasized a large untreated/under-treated anticoagulant market opportunity if milvexian shows a better bleeding profile.

(8/9) Q&A: What is being done to reverse Abiomed Q2 softness and what is the growth outlook?
• ⚠️ Management attributed the slowdown to physician caution after a neutral U.K. high-risk PCI study, calling it behavioral rather than structural.
• 📚 J&J is engaging physicians on appropriate selection using a deep evidence base, while PROTECT 4 remains a highly powered 2027 readout.
• 📈 Performance is expected to improve in the back half and gradually return toward double-digit growth over coming quarters without changing enterprise growth trajectory.

(9/9) Q&A: Why is SKYRIZI holding share if TREMFYA has an edge in GI?
• 💰 TREMFYA posted a first $2 billion quarter with over 70% growth, led primarily by ulcerative colitis and Crohn’s performance.
• 📊 J&J claims induction share leadership among IL-23s, including about 58% in UC and over 50% in Crohn’s.
• 🩺 Fusion data in perianal fistulizing Crohn’s and convenient subcu induction/auto-injector presentation are cited as further receptivity drivers.